Research of anti-tumor effect at non-treated site by carbon-ion radiotherapy combined with immunotherapy
| Project/Area Number |
17K16423
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
MA LIQIU 群馬大学, 重粒子線医学推進機構, 研究員 (70711539)
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 重粒子線 / 免疫 / 転移抑制 / 遠隔腫瘍制御 / 炭素イオン線 / 免疫療法 / アブスコパル効果 |
|---|
| Outline of Final Research Achievements |
In this study, the changes of anti-tumor immunity after carbon-ion radiotherapy (CIRT) had been analyzed by tumor bearing mouse model. After local CIRT, immunogenic cell death-related “eat me” signals released from dying tumor cells, then immune checkpoint molecular PD-L1 expression increased in cell surface. To improve CIRT, we aimed to find an optimal combination therapy for CIRT. In the current study, we evaluated immune checkpoint inhibitors (anti-PD-1 antibody or anti-CTLA4 antibody). Only anti-CTLA4 antibody combined with 3 Gy CIRT showed significantly suppression of pulmonary metastasis, irradiated and un-irradiated tumor proliferation.
|
| Academic Significance and Societal Importance of the Research Achievements |
本課題で、マウス担癌モデルを用いて重粒子線と抗CTLA4抗体併用により肺転移、照射側腫瘍と照射されていない遠隔に存在する腫瘍も抑制できることを科学的に示した。この研究成果により、局所制御において良好な成績を示している重粒子線療法と抗CTLA4抗体免疫療法併用において、CTやPETで診断できないような微小転移、照射不可能な転移および多臓器転移などの照射されていない遠隔腫瘍を制御する可能性を示し、より広範囲のがん患者への適応や治療成績の向上に繋がることが期待される。
|
Report
(3 results)
Research Products
(7 results)
